Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Prostate Cancer Metastatic”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Active Not RecruitingNCT04493853
What this trial is testing

Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

Who this might be right for
Hormone-Sensitive Prostate Cancer
AstraZeneca 1,012
Not applicableStudy completedNCT00002981
What this trial is testing

PET Scan in Treating Patients With Metastatic Prostate Cancer

Who this might be right for
Prostate Cancer
Memorial Sloan Kettering Cancer Center 173
Testing effectiveness (Phase 2)Study completedNCT02047253
What this trial is testing

Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
University of Alabama at Birmingham 28
Large-scale testing (Phase 3)Active Not RecruitingNCT04497844
What this trial is testing

Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)

Who this might be right for
Prostatic Neoplasms
Janssen Research & Development, LLC 696
Not applicableLooking for participantsNCT04075305
What this trial is testing

The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study

Who this might be right for
OncologyBreast CancerProstate Cancer+35 more
UMC Utrecht 8,000
Testing effectiveness (Phase 2)UnknownNCT05268666
What this trial is testing

Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors

Who this might be right for
Locally Advanced Solid TumorMetastatic Solid Tumor
Jubilant Therapeutics Inc. 126
Large-scale testing (Phase 3)Study completedNCT01930812
What this trial is testing

18F-NaF PET Imaging for Bone Scintigraphy

Who this might be right for
Bone Metastases From Breast or Prostate Cancer
British Columbia Cancer Agency 286
Early research (Phase 1)Looking for participantsNCT07621692
What this trial is testing

Exploring Auger-Enhanced PSMA-Targeted Radioligand Therapy: A First-in-Taiwan Clinical Study of 161Tb-PSMA-I&T

Who this might be right for
Metastatic Castration Resistant Prostate Cancer (mCRPC)
National Taiwan University Hospital 12
Testing effectiveness (Phase 2)Study completedNCT03336983
What this trial is testing

Luteinizing Hormone-releasing Hormone Analogue and Enzalutamide +/- Zoledronic Acid in Prostate Cancer Patients

Who this might be right for
Prostate CancerBone Metastases
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia 126
Testing effectiveness (Phase 2)UnknownNCT04486937
What this trial is testing

SC10914 Monotherapy for the mCRPC With g/s BRCA Mutation

Who this might be right for
Metastatic Castration Resistant Prostate Cancer
Jiangxi Qingfeng Pharmaceutical Co. Ltd. 90
Testing effectiveness (Phase 2)UnknownNCT02484339
What this trial is testing

Treatment of Advanced Castration Resistant Prostate Carcinoma With Limited Bone Metastases (α-RT)

Who this might be right for
Prostate Carcinoma
University Hospital Freiburg 274
Large-scale testing (Phase 3)Looking for participantsNCT06496581
What this trial is testing

Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)

Who this might be right for
Prostate Cancer Metastatic
UNICANCER 500
Large-scale testing (Phase 3)Ended earlyNCT00294437
What this trial is testing

ZOMETA® (Zoledronic Acid) for Prevention of Bone Metastases

Who this might be right for
Prostate Cancer
Central European Cooperative Oncology Group 376
Large-scale testing (Phase 3)Looking for participantsNCT06855277
What this trial is testing

Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

Who this might be right for
Prostate Cancer
Novartis Pharmaceuticals 940
Testing effectiveness (Phase 2)Study completedNCT00450619
What this trial is testing

153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer

Who this might be right for
Prostate Cancer
National Cancer Institute (NCI) 44
Early research (Phase 1)Study completedNCT00375245
What this trial is testing

Rapamycin With Grapefruit Juice for Advanced Malignancies

Who this might be right for
TumorsNeoplasm Metastasis
University of Chicago 41
Testing effectiveness (Phase 2)Study completedNCT02125357
What this trial is testing

Sequencing Abiraterone and Enzalutamide in mCRPC

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer
British Columbia Cancer Agency 202
Large-scale testing (Phase 3)Study completedNCT03016312
What this trial is testing

Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen

Who this might be right for
Prostatic Neoplasms, Castration-Resistant
Hoffmann-La Roche 759
Testing effectiveness (Phase 2)Ended earlyNCT03741712
What this trial is testing

SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC

Who this might be right for
Prostate CancerCastration-resistant Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd. 9
Testing effectiveness (Phase 2)Study completedNCT01718353
What this trial is testing

Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Who this might be right for
Prostate Cancer Metastatic
Sanofi 63
Next Page